ANT-GROUP
5.3.2024 12:28:33 CET | Business Wire | Press release
For the third consecutive year, Ant Group, a global digital technology provider, has been recognized as a Top 100 Global Innovator™ 2024 by Clarivate™, a global leader in connecting people and organizations to intelligence they can trust to transform their world. This recognition reaffirms Ant Group's ongoing commitment to innovation excellence in technologies such as artificial intelligence (AI) and blockchain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305020027/en/
Clarivate recognizes Ant Group as one of the Top 100 Global Innovators 2024 (Graphic: Business Wire)
Gordon Samson, President, Intellectual Property, Clarivate, said, “We congratulate Ant Group for being named as a Top 100 Global Innovator again. To feature as a Top 100 Global Innovator is no mean feat as maintaining an edge in the innovation ecosystem is harder than ever. Organizations must balance experimentation and risk with discipline and reward. We measure and rank innovative performance in a dynamic and thorough way, using live thresholds of differentiation. At Clarivate, we think forward by analyzing the quality of ideas, their potency and their impact to identify the world’s top innovators, and this year we reveal the ranking of these innovators for the first time.”
As of the end of 2023, Ant Group had filed 32,459 patent applications globally, with 22,102 patents granted. The top three categories of these patent applications are security technology, blockchain and AI.
"Our recognition by Clarivate as one of the Top 100 Global Innovators is a testament to our innovation capabilities," said Shen PAN, Director of Patents at Ant Group. "We are committed to leveraging technology to build trust and accelerate digital transformation across industries. Our journey is driven by our advancements in key technologies such as blockchain, privacy computing, security technology, Internet of Things (IoT) databases, and most notably, AI.”
In the field of AI, Ant Group has been continuously leveraging its technology to enhance the user experience across its product offerings for years. As of the end of 2023, Ant Group had filed over 3,000 AI-related patents. During Alipay’s 2024 Chinese New Year campaign, AI features in the app attracted 600 million interactions.
To facilitate technological advancement across industries, Ant Group has been making its innovations publicly accessible to developers in the open-source community. For example, Ant Group’s AI infrastructure team open-sourced ATorch, an extension library of PyTorch, that can improve GPU utilization rate up to 60% in large-scale pre-trainings of Large Language Models (LLMs). Meanwhile, the company’s open-sourced Lookahead achieves lossless generation accuracy for LLMs while boosting the inference speeds of LLMs by 2 to 6 times.
By the end of 2023, the number of open-source repositories from Ant Group on platforms such as GitHub had exceeded 1,900. Additionally, according to the 2023 Blue Paper on the Development of Open Source in China published by China OSS Promotion Union (COPU), Ant Group is recognized as one of the top three organizations in the country in terms of open-source contributions and influence.
Leveraging its innovations in technologies such as blockchain, privacy computing, security technology, IoT, and databases, Ant Group provides technology products and services to support the digital transformation and collaboration of global enterprise customers across a variety of industries. These industries include banking, telecommunication, real estate, medicine and energy. The company has garnered recognition from various organizations for its excellence in delivering innovative products and services to customers. For example, AntChain was recognized by Forbes on the Blockchain 50 list for five consecutive years (from 2019 to 2023). In September 2023, ZOLOZ was named as a Representative Vendor for the second consecutive time in the latest Gartner Market Guide for Identity Verification.
Methodology
The Top 100 Global Innovators uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power.
To move from the individual idea strength to identify the organizations that create them more consistently and frequently, Clarivate sets two threshold criteria that potential candidates must meet and then adds a measure of their patented innovation output over the past five years.
For full information on the methodology used to identify the 2024 list, see here.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
About Ant Group
Ant Group traces its roots back to Alipay, which was established in 2004 to create trust between online sellers and buyers. Over the years, Ant Group has grown to become one of the world's leading open Internet platforms.
Through technological innovation, Ant Group supports its partners in providing inclusive, convenient digital life and digital financial services to consumers and SMEs. In addition, it has been introducing new technologies and products to support the digital transformation of industries and facilitate industrial collaboration. Working together with global partners, the company enables merchants and consumers to make and receive payments and remit around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305020027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom